Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place

被引：0
|
作者：
Jurascheck, L. [1 ]
Van de Putte, Fransen E. [2 ]
Van den Brink, L. [3 ]
Van der Mijn, J. C. [4 ]
Wilgenhof, S. [4 ]
Van Thienen, J. V. [4 ]
Haanen, J. B. A. G. [4 ]
Boleti, E. [5 ]
Powles, T. [6 ]
Zondervan, P. J. [3 ]
Graafland, N. M. [2 ]
Bex, A. [1 ]
机构：
[1] Royal Free London NHS Fdn Trust, Dept Urol, London, England
[2] Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands
[3] Amsterdam UMC, Dept Urol, Amsterdam, Netherlands
[4] Netherlands Canc Inst, Dept Oncol, Amsterdam, Netherlands
[5] Royal Free NHS Fdn Trust, Dept Oncol, London, England
[6] Barts Canc Ctr, Dept Oncol, London, England
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0838
引用
收藏
页码：S1859 / S1860
页数：2
相关论文
共 50 条
  • [1] Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place
    Meerveld-Eggink, A.
    Graafland, N.
    Wilgenhof, S.
    Van Thienen, J. V.
    Grant, M.
    Szabados, B. E.
    Abu-Ghanem, Y.
    Boleti, E.
    Blank, C. U.
    Haanen, J. B. A. G.
    Powles, T. B.
    Bex, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S575 - S575
  • [2] Primary Renal Tumour Response in Patients Treated with Nivolumab and Ipilimumab for Metastatic Renal Cell Carcinoma: Real-world Data Assessment
    Meerveld-Eggink, Aafke
    Graafland, Niels
    Wilgenhof, Sofie
    Van Thienen, Johannes V.
    Lalezari, Ferry
    Grant, Michael
    Szabados, Bernadett
    Abu-Ghanem, Yasmin
    Kuusk, Teele
    Boleti, Ekaterini
    Blank, Christian U.
    Haanen, John B. A. G.
    Powles, Thomas
    Bex, Axel
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 35 : 54 - 58
  • [3] Real-world safety and efficacy data of patients with synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N plus I) and the primary tumour (PT) in place.
    Meerveld-Eggink, Aafke
    Graafland, Niels
    Wilgenhof, Sofie
    Van Thienen, Johannes V.
    Grant, Michael
    Szabados, Bernadett
    Abu-Ghanem, Yasmin
    Boleti, Ekaterini
    Blank, Christian U.
    Haanen, John B. A. G.
    Powles, Thomas
    Bex, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy
    Takagi, Toshio
    Yoshida, Kazuhiko
    Kondo, Tsunenori
    Fukuda, Hironori
    Ishihara, Hiroki
    Kobayashi, Hirohito
    Iizuka, Junpei
    Ishida, Hideki
    Tanabe, Kazunari
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (12) : 1744 - 1750
  • [5] Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma
    Numakura, Kazuyuki
    Sekine, Yuya
    Hatakeyama, Shingo
    Muto, Yumina
    Sobu, Ryuta
    Kobayashi, Mizuki
    Sasagawa, Hajime
    Kashima, Soki
    Yamamto, Ryohei
    Nara, Taketoshi
    Akashi, Hideo
    Tabata, Ryuji
    Sato, Satoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    CANCER MEDICINE, 2023, 12 (16): : 16837 - 16845
  • [6] Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab
    Brown, Landon C.
    Desai, Kunal
    Wei, Wei
    Kinsey, Emily N.
    Kao, Chester
    George, Daniel J.
    Rini, Brian, I
    Ornstein, Moshe C.
    Zhang, Tian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (09)
  • [7] Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab
    Beulque, Yana
    Kinget, Lisa
    Roussel, Eduard
    Mobaraki, Sajedeh
    Laenen, Annouschka
    Debruyne, Philip R.
    Van Herck, Yannick
    Baldewijns, Marcella
    Wozniak, Agnieszka
    Garg, Abhishek D.
    Zucman-Rossi, Jessica
    Couchy, Gabrielle
    Albersen, Maarten
    De Wever, Liesbeth
    Haaker, Lorenz
    Beuselinck, Benoit
    ACTA ONCOLOGICA, 2024, 63 : 658 - 668
  • [8] Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Yoshino, Maki
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Nishimura, Koichi
    Tachibana, Hidekazu
    Fukuda, Hironori
    Toki, Daisuke
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Tanabe, Kazunari
    Kondo, Tsunenori
    Takagi, Toshio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1208 - 1214
  • [9] Multicenter retrospective analysis of patients with metastatic renal cell carcinoma (mRCC) and bone metastases treated with ipilimumab and nivolumab
    Desai, Kunal
    Brown, Landon Carter
    Wei, Wei
    Allman, Kimberly D.
    Martin, Allison
    Wood, Laura S.
    Gupta, Shilpa
    Gilligan, Timothy D.
    Garcia, Jorge A.
    Kao, Chester
    Kinsey, Emily Noelle
    Healy, Patrick
    Kephart, Julie
    Harrison, Michael Roger
    Ramalingam, Sundhar
    Armstrong, Andrew J.
    George, Daniel J.
    Rini, Brian I.
    Zhang, Tian
    Ornstein, Moshe Chaim
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [10] POTENTIAL SURVIVAL BENEFIT OF DEFERRED NEPHRECTOMY IN PATIENTS TREATED WITH NIVOLUMAB PLUS IPILIMUMAB FOR METASTATIC RENAL CELL CARCINOMA
    Yoshino, Maki
    Ishihara, Hiroki
    Nemoto, Yuki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Hiroaki, Shimmura
    Hashimoto, Yasunobu
    Takagi, Toshio
    Kondo, Tsunenori
    Tanabe, Kazunari
    JOURNAL OF UROLOGY, 2022, 207 (05): : E170 - E170
12345